Inaugural Interdisciplinary Symposium on Mechanical Circulation Support (MCS)

On Saturday, December 1, 2018, the University Hospital of Zurich (USZ), Switzerland, led by the ECMO team under the direction of Max Halbe, Chief Perfusionist, hosted its first interdisciplinary symposium, Mechanical Circulation Support (MCS,) in the hospital facilities.  More than 80 participants from the medical field, predominantly medical doctors and perfusionists, attended the inaugural event.

Well renowned speakers from Switzerland and Germany from a cross-section of disciplines such as anesthesiology, cardiac surgery, intensive care medicine, cardiology and perfusion presented the historical background as well as the current state in mechanical circulation support including such technical aspects as cannulation and venting.  The presentations clearly demonstrated that there is a current trend in the increased use of techniques such as extracorporeal membrane oxygenation (ECMO) / extracorporeal life support (ECLS) and other forms of mechanical circulation support.

The day began with introductory talks by Professors Ruschitzka and Wilhelm that stressed the importance for medical practitioners to bear in mind that when treating patients requiring mechanical circulatory support, often, if not in all instances, systemic hyperinflammation is present too, and plays a crucial role that can affect the further clinical course of the patient and potentially impact on the final outcome.  Appropriate treatment strategies should therefore not only focus on the circulation support itself, but also on the hyperinflammatory situation present.

The afternoon sessions included practical workshops on cardiogenic shock, septic shock and Impella use, and offered insights into the technical set up of mechanical circulation support which included the integration of the CytoSorb adsorber into an ECLS circuit.

All in all, it was a day filled with informative and engaging presentations on this increasingly effective and promising therapy outlining the pathophysiologic rationale for its use and, equally as important, guidance was also provided for the practical application.

Next years’ event has already been announced for November 30, 2019 and we look forward to rejoining our colleagues and learning how the use of these therapies evolves over the coming months.

CytoSorb Literature Database

During your daily work at the patients’ bedside or when doing research in preparation for a lecture or a publication, you would love to gather a broad overview of the available literature surrounding CytoSorb therapy.

The core of our new Literature Database is its structured keyword search tool, which provides a sophisticated search engine, adapted to your current issue:

  • combine key words on different levels: document type, indication, outcome, adsorption target, environment, platform, publication date, document language or
  • search within the available text for example an author or other terms.

The search results contain short summaries or released full text. Follow the link to source (for e.g. or download released PDF’s (i.e. Case of the week).

We are certain that this easy to use tool with its extensive overview of CytoSorb literature will be of major benefit for you. As always our goal is to provide you with useful tools, in order to give you the best possible support.

For quick and easy access to the CytoSorb Literature Database, bookmark the following link:

Discover the new CytoSorb Literature Database now  – we look forward to hearing your opinion!


The Roger-Bone-Prize for clinical sepsis research, selected by the German Sepsis Society, is awarded every year to young scientists from German speaking countries. CytoSorbents Europe is happy to once again support this research prize. We congratulate Dr. Christian Scheer from the Anesthesiology Clinic, Greifswald University hospital (Germany), who received the Roger-Bone-Prize 2017 during the 2017 Sepsis Update Congress in Weimar for his publication „Quality improvement initiative for severe sepsis and septic shock reduces 90-day mortality: A 7.5-year observational study“ (Crit Care Med 2017; 45(2):241-252).

Successful 4th International CytoSorb Users Meeting – 2017

The day before the start of the 37th ISICEM, the 4th International Users Meeting brought together 120 CytoSorb users and other interested parties from a total of 22 countries. The international faculty shared an update on the latest scientific findings, recent study results and case series in different patient groups, followed by a podium discussion.
>> read more

Case Series & Reports

CytoSorbents Reports on Successful 3rd International CytoSorb® Users Meeting

Continued Flow of Data Correlating Positive Clinical Improvements with CytoSorb® Usage

BRUSSELS, BELGIUM, March 16, 2016 – CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb® blood filtration technology to reduce deadly uncontrolled inflammation in critically-ill and cardiac surgery patients around the world, announced the conclusion of its successful 3rd International CytoSorb Users Meeting in Brussels, Belgium. Held one day ahead of the International Symposium of Intensive Care and Emergency Medicine (ISICEM), one of the largest international critical care conferences, the Users Meeting brought together 107 members of the CytoSorb® community from a total of 23 countries, to share data from many new pre-clinical and clinical studies. To date, more than 10,000 CytoSorb® treatments have been performed in thousands of patients.

Some of the most important findings include:

  • In addition to cytokines, CytoSorb® has been shown to remove a broad range of other inflammatory mediators called pathogen (PAMPs) and damage (DAMPs) associated molecular patterns, which play an important role in inducing systemic inflammation in a wide range of critical illnesses. PAMPs are toxins produced or released by bacteria, viruses and fungi that can cause tissue injury or inflammation. DAMPs originate from damaged or necrotic tissue, like HMGB-1, S100 protein, procalcitonin, and activated complement, and are also toxic in excessive quantities. DAMPs and PAMPs are a leading focus of international research on the uncontrolled systemic inflammatory response syndrome
  • The intra-operative application of CytoSorb® in an ongoing three-arm randomized controlled open heart surgery study in Cologne, Germany was associated with a statistically significant decrease in sternal wound infections, a major complication of cardiac surgery with a total of 165 patients enrolled to date
  • In a cardiac surgery evaluation performed at Angers, France, CytoSorb® was used intra-operatively on 10 patients undergoing a diverse set of complex cardiac surgery procedures, similar to patients in the U.S. REFRESH I trial. All ten patients did well, with CytoSorb® credited with helping to stabilize two hemodynamically unstable patients going into extensive and complicated surgery, and reducing the need for vasopressors and extensive, costly, and risky extracorporeal life support that would normally be required in the post-operative period in these patients
  • Four different independent septic shock case series totaling more than 50 treated patients with severe or refractory shock, have all reported a consistent stabilization of the cardiovascular system following treatment, with a reduction in vasopressor support
  • Several studies have suggested that early intervention with aggressive treatment is superior to late intervention in terms of clinical outcomes
  • New systematic data, confirming previous observations, that CytoSorb® can effectively remove liver toxins such as bilirubin, in some cases better than established liver support therapies
  • All of the presenters once again reiterated the safety of the device in all reported applications
  • An update on the start of the PACIFICA trial, using CytoSorb to treat severe acute pancreatitis
  • Reiteration that CytoSorb® is a useful therapy to reduce extensive myoglobinemia that occurs due to rhabdomyolysis due to trauma, burns, or infection

Dr. Phillip Chan, Chief Executive Officer, stated,

“We are pleased to report this initial summary of the 3rd International CytoSorb® Users Meeting. The purpose of these meetings is to disseminate the lessons learned from experienced users so that we can ensure uniformity of treatment and that all users worldwide benefit from the latest information. Although there is always more to learn, we are pleased to see that when CytoSorb® is used in the right way, users continue to experience positive results with the treatment. As we have done in the past, a more detailed report of this meeting will be published in a proceedings booklet that will be available at our CytoSorb website.”